Cambridge Investment Research Advisors
AUPH icon

Cambridge Investment Research Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,396
Closed -$135K – 3091
2021
Q2 		$135K Buy
+10,396
New +$132K ﹤0.01% 2921

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Cambridge Investment Research Advisors's AUPH Position: Q3 2021 in Review

Cambridge Investment Research Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 10,396 shares — an estimated $135K sold.

Cambridge Investment Research Advisors first reported a position in AUPH in Q2 2021 and held it in 1 quarter. The position peaked at $135K in Q2 2021. 166 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

  • Cambridge Investment Research Advisors reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 10,396 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $135K.
  • Cambridge Investment Research Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Aurinia Pharmaceuticals position peaked at $135K in Q2 2021.
  • 166 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.